The present invention relates to a novel member of the tumor necrosis factor
family of receptors. In particular, isolated nucleic acid molecules are provided
encoding the human TR9 receptor. TR9 polypeptides are also provided as are antibodies,
vectors, host cells and recombinant methods for producing the same. The invention
further relates to screening methods for identifying agonists and antagonists of
TR9 receptor activity.
